A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer
NCT05902988
This study is recruiting at 13 US sites in 12 states, according to its ClinicalTrials.gov record last updated .
Summary
This is a first-in-human phase I/II study to examine the safety, tolerability and preliminary efficacy of VLS-1488 in subjects with advanced cancers.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Advanced Solid Tumor
- High Grade Serous Adenocarcinoma of Ovary
- Squamous Non-small-cell Lung Cancer
- Triple Negative Breast Cancer
- Head and Neck Squamous Cell Carcinoma
- Ovarian Carcinosarcoma
- Uterine Carcinosarcoma
- Uterine Serous Carcinoma
- Endometrium Cancer
- Chromosomal Instability
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Volastra Therapeutics, Inc.
- Last updated on ClinicalTrials.gov
- November 4, 2025
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 2
- University of Southern California · Los Angeles, CA
- Hoag Memorial Hospital · Newport Beach, CA
Colorado · 1
- University of Colorado Cancer Center · Aurora, CO
Connecticut · 1
- Yale Cancer Center · New Haven, CT
Illinois · 1
- Kellogg Cancer Center · Evanston, IL
Indiana · 1
- Community Health Network · Indianapolis, IN
Maryland · 1
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center · Baltimore, MD
Michigan · 1
- University of Michigan · Ann Arbor, MI
New York · 1
- Memorial Sloan Kettering Cancer Center · New York, NY
Ohio · 1
- The Christ Hospital · Cincinnati, OH
Rhode Island · 1
- Women & Infants Hospital · Providence, RI
Texas · 1
- M.D. Anderson Cancer Center · Houston, TX
Wisconsin · 1
- Froedtert & the Medical College of Wisconsin · Milwaukee, WI
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.